XOMA Presents Data On XOMA 052, An Anti-IL-1 Beta Antibody, in Rheumatoid Arthritis and Acute Gout Animal Models Oct 25, 2008 8:00pm EDT
XOMA to Webcast Analyst and Investor Event 'Interleukin-1 Blockers: Unlocking Their Potential in Diabetes and Beyond' On September 25 Sep 22, 2008 8:05am EDT
XOMA Awarded $65 Million Biodefense Contract by NIAID to Advance Drug Candidates Against Botulism Toxins Into Clinical Trials Sep 09, 2008 1:57pm EDT
XOMA 052 Clinical Results Support New Type 2 Diabetes Therapeutic Approach of Targeting Inflammatory Damage to Insulin-Producing Cells Sep 08, 2008 5:00am EDT
XOMA Begins Phase 2a Clinical Trial to Evaluate XOMA 629 Topical Gel as a Treatment for the Common Skin Disease, Impetigo Jul 24, 2008 4:41pm EDT
